Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 402 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: PAH Clear all
Completed Phase 2 Interventional Results available

Anastrozole in Patients With Pulmonary Arterial Hypertension

NCT01545336
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Anastrozole, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 23, 2026, 6:43 AM EDT
Completed Not applicable Interventional Results available

A Mobile Health Intervention in Pulmonary Arterial Hypertension

NCT03069716
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Associated Pulmonary Arterial Hypertension
Interventions
Smartphone Text Messaging, Fitbit Charge HR
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 23, 2026, 6:43 AM EDT
Completed Phase 1 Interventional

Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension

NCT03926793
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
GB002, Placebo, Generic Dry Powder Inhaler
Drug · Device
Lead sponsor
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
La Jolla, California • Sacramento, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 23, 2026, 6:43 AM EDT
Terminated Phase 3 Interventional Results available

A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

NCT03657095
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Esuberaprost, Placebo
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
18 Years to 85 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 23, 2026, 6:43 AM EDT
Completed Phase 2 Interventional Results available

A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)

NCT04712669
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo
Drug
Lead sponsor
Altavant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
28
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 23, 2026, 6:43 AM EDT
Terminated Phase 3 Interventional Results available

Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)

NCT05557942
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
AV-101
Drug
Lead sponsor
Aerovate Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
16
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 23, 2026, 6:43 AM EDT
Completed No phase listed Observational

The Effects of Drug Candidate CS1 on Lung Structure and Function Utilizing FRI

NCT06907693
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
CT Pulmonary Angiography Scan
Diagnostic Test
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 6:43 AM EDT
Terminated Phase 1 Interventional Results available

Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

NCT02981082
View directory record Official record
Conditions
Systemic Sclerosis, Pulmonary; Hypertension
Interventions
Dimethyl Fumarate (DMF), Placebo Oral Tablet
Drug
Lead sponsor
Robert Lafyatis
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 23, 2026, 6:43 AM EDT
Completed No phase listed Observational

Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States

NCT03197688
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Notapplicable
Other
Lead sponsor
Actelion
Industry
Eligibility
Not listed
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
105
States / cities
Phoenix, Arizona • La Jolla, California • Loma Linda, California + 89 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 23, 2026, 6:43 AM EDT
Completed No phase listed Observational Results available

A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension

NCT01028651
View directory record Official record
Conditions
Portopulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions
Treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 23, 2026, 6:43 AM EDT
Active, not recruiting Phase 4 Interventional

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

NCT05203510
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Parenteral Treprostinil, Oral Treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
28
States / cities
Phoenix, Arizona • Fresno, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 23, 2026, 6:43 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Angiogenic Imaging in Pulmonary Arterial Hypertension

NCT03166306
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Exercise Associated Pulmonary Arterial Hypertension
Interventions
PET-CT Imaging with [89Zr]-bevacizumab
Diagnostic Test
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 23, 2026, 6:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Novel Screening Strategies for Scleroderma PAH

NCT01959815
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Scleroderma
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
30 Years and older
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Oct 23, 2026, 6:43 AM EDT
Terminated No phase listed Observational

Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin

NCT05060315
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Remunity Pump for Remodulin
Combination Product
Lead sponsor
United Therapeutics
Industry
Eligibility
22 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 23, 2026, 6:43 AM EDT
Active, not recruiting Not applicable Interventional

Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension

NCT06477640
View directory record Official record
Conditions
Pulmonary Arterial Hypertension PAH
Interventions
Exercise, Standard of Care
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 23, 2026, 6:43 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Hormonal, Metabolic, and Signaling Interactions in PAH

NCT01884051
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Scleroderma Associated Pulmonary Arterial Hypertension, Appetite Suppressant Associate PAH
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 90 Years
Enrollment
1,899 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2032
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 6:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities

NCT01165476
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil diethanolamine
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 23, 2026, 6:43 AM EDT
Withdrawn Phase 4 Interventional

Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil

NCT00625079
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Pulmonary Hypertension
Interventions
sildenafil
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 23, 2026, 6:43 AM EDT
Recruiting No phase listed Observational

Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry

NCT02249923
View directory record Official record
Conditions
Pulmonary Vascular Disease, Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
New York Medical College
Other
Eligibility
1 Day to 21 Years
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2031
U.S. locations
13
States / cities
Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 23, 2026, 6:43 AM EDT
Recruiting No phase listed Observational

Pulmonary Hypertension Biorepository and Registry

NCT04808596
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension, Primary, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Primary, 4, Pulmonary Hypertension, Primary, 2, Pulmonary Hypertension, Primary, 3, Chronic Thromboembolic Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Timeline
2020 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 23, 2026, 6:43 AM EDT
Completed Phase 2 Interventional

Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)

NCT01966302
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
BPS-314d-MR
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 23, 2026, 6:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Pulmonary Perfusion Heterogeneity and Compliance in Patients With Pulmonary Hypertension Using Positron Emission Tomography Imaging

NCT01461343
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
CT imaging, functional PET imaging
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 23, 2026, 6:43 AM EDT
Completed No phase listed Observational

A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)

NCT04813926
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Riociguat (Adempas, BAY63-2521)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
49
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 23, 2026, 6:43 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension

NCT03187678
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
i.v. selexipag, oral selexipag (Uptravi)
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
La Jolla, California • Boston, Massachusetts • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 23, 2026, 6:43 AM EDT